Develops biologic drug candidates for interstitial lung disease and other fibrotic and inflammatory diseases, including efzofitimod for pulmonary sarcoidosis and systemic sclerosis-related lung disease.
10-K for FY2025, filed Mar 5, 2026We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies…View ↗
Our lead therapeutic candidate is efzofitimod, a novel biologic immunomodulator in clinical development for the treatment of interstitial…View ↗
We believe efzofitimod has potential applications in the treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and…View ↗
Partners pay through upfront and milestone payments for development and commercialization rights, with royalties on product sales; the company may also receive payment for research and development services over time.
10-K for FY2025, filed Mar 5, 2026
$190K
10-K for FY2025, filed Mar 5, 2026
$190K ↗
The company licenses efzofitimod rights to a pharmaceutical partner for development and commercialization in Japan; the partner funds activities there. The company also supplies drug product and supports development.
10-K for FY2025, filed Mar 5, 2026
No. It lost $74.1M in FY2025.
10-Q for Q3 FY2026, filed Nov 6, 2026
−$18.3MView ↗
8-K, filed Sep 24, 2026
On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration…View ↗
8-K, filed Jul 31, 2026
On July 30, 2026, the Company and Kyorin entered into a termination agreement (“Termination Agreement”) whereby the parties mutually agreed…View ↗
Added a commercial-transition goal
The latest report adds plans to move from clinical-stage biotechnology toward a commercial pharmaceutical company and begin U.S. pre-commercialization efforts; the older report described clinical development and pipeline expansion.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 5, 2026Transition from a clinical stage biotech to a commercial pharmaceutical company. We have begun pre-commercialization efforts in the U.S.…View ↗
Advance efzofitimod toward regulatory approval in pulmonary sarcoidosis. In September 2025, we announced top-line data from the EFZO-FIT…View ↗
Build a diverse pipeline of biologics product candidates based on our understanding of extracellular tRNA synthetase biology. Utilizing our…View ↗
Competes with Boehringer Ingelheim International GmbH, Bristol Myers Squibb, Merck &, Sanofi-Aventis, GSK, and United Therapeutics
10-K for FY2025, filed Mar 5, 2026There are a number of companies engaged in the clinical development of potential new treatments for ILD, including Boehringer Ingelheim…View ↗
Loading...